References
- Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
- Yiwei H. China's diabetes epidemic in charts CGTN.com: CGTN2019. [updated 14 November 2020; cited 2020 September 2, 2021]. Available from: https://news.cgtn.com/news/2019-11-14/China-s-diabetes-epidemic-in-charts-LC60vrsOv6/index.html.
- American Diabetes Association (ADA). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Suppl. 1):S98–S110.
- Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625–1660.
- Wu L, Zhao L, Su X, et al. Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. Drug Deliv. 2020;27(1):400–409.
- U.S. Food and Drug Administration. NovoLog: full prescribing information. [cited 2020 Aug 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020986s057lbl.pdf2008.
- Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 1999;55(3):199–203.
- Hermansen K, Bohl M, Schioldan A. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs. 2016;76(1):41–74.
- Diabetes Branch of Chinese Medical Association 中国2型糖尿病防治指南(2017, 年版)<China type 2 diabetes prevention guidelines (2017 edition)> [Chinese]. Chin J Diabetes Mellitus. 2018;10(1):4–67.
- Mbanya JC, Sandow J, Landgraf W, et al. Recombinant human insulin in global diabetes management – focus on clinical efficacy. Eur Endocrinol. 2017;13(1):21–25.
- Pala L, Mannucci E, Dicembrini I, et al. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;78(1):132–135.
- Randeree H, Liebl A, Hajjaji I, et al. Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis. Diabetes Ther. 2013;4(1):153–166.
- Chlup R, Zapletalová J, Sečkař P, et al. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diabetes Technol Ther. 2007;9(3):223–231.
- Plum-Mörschel L, Uhrmacher E, Zijlstra E, et al. Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) To US- And EUlicensed Insulin Aspart (ASP). EASD Virtual Meeting; 2021.
- European Medicines Agency. NovoRapid: summary of product information. [cited 2020 Aug 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/novorapid-epar-product-information_en.pdf2019.
- Su L. Reducing the China “Drug Lag”: 2017 CFDA Metrics. [cited 2021 Feb 4]. Available from: https://globalforum.diaglobal.org/issue/april-2018/reducing-the-china-drug-lag-2017-cfda-metrics/2018.
- Cai X, Shi L, Yang W, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ. 2019;22(4):336–343.
- Endocrinology Branch of Chinese Medical Association 成人2型糖尿病胰岛素临床应用中国专家共识 <Chinese expert consensus on the clinical application of insulin in adult type 2 diabetes mellitus> [Chinese]. Chin J Endocrinol Metab. 2013;29(1):1–6.
- Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia. Diabetes Care. 2005;28(5):1245–1249.
- International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American diabetes association and the European Association for the study of diabetes. Diabetes Care. 2017;40(1):155–157.
- US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. [cited 2021 Feb 12]. Available from: https://docplayer.net/5967402-Guidance-for-industry-diabetes-mellitus-developing-drugs-and-therapeutic-biologics-for-treatment-and-prevention.html.
- American Diabetes Association. Glycemic targets. Diabetes Care. 2016;39(1):S39–S46.
- International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103:256–268.
- Madsbad S. Impact of postprandial glucose control on diabetes related complications: how is the evidence evolving? J Diabetes Complications. 2016;30(2):374–385.
- Shafie AA, Gupta V, Baabbad R, et al. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2014;106(2):319–327.
- Bott U, Ebrahim S, Hirschberger S, et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type I diabetes. Diabet Med. 2003;20(8):626–634.
- Home PD, Hallgren P, Usadel KH, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006;71(2):131–139.
- Cucinotta D, Caputo S, Mannucci E, et al. Safety and efficacy of insulin aspart and soluble human insulin in type 2 diabetes mellitus. Minerva Endocrinol. 2012;37(4):357–366.
- Heinemann L. Biosimilar insulin and costs: what can we expect? J Diabetes Sci Technol. 2015;10(2):457–462.
- Ewen M, Joosse H-J, Beran D, et al. Insulin prices, availability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019;4(3):e001410-e001410.
- European Medicines Agency. Insulin lispro Sanofi: summary of product characteristics. [cited 2020 Aug 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/insulin-lispro-sanofi-epar-product-information_en.pdf2017.
- U.S. Food and Drug Administration. ADMELOG: Full Prescribing Information. [cited 2020 Aug 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209196s000lbl.pdf2017.
- European Medicines Agency. Insulin aspart Sanofi: summary of product information. [cited 2020 Aug 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/insulin-aspart-sanofi-epar-product-information_en.pdf2020.
- Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized Open-Label trial (GEMELLI 1). Diabetes Technol Ther. 2020;22(2):85–95.
- European Medicines Agency. Clinical investigation of medicinal products in the treatment of diabetes mellitus, draft January 2018 [cited 2021 Feb 12]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf.
- Bode BW, Iotova V, Kovarenko M, et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial. Diabetes Care. 2019;42(7):1255–1262.
- Ma RCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249–1260.
- Rodbard HW, Tripathy D, Vidrio Velázquez M, et al. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes Obes Metab. 2017;19(10):1389–1396.
- Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4(10):661–667.
- Klingensmith G. Insulin antibodies–are they still with us? Do they matter? Pediatr Diabetes. 2011;12(2):75–77.
- Lindholm A, Jensen L, Home P, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25(5):876–882.
- Atkinson M, Eisenbarth G. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–229.